SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 vaccine. - Archive ouverte HAL Access content directly
Conference Poster Year :

SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 vaccine.

(1) , (2) , (3) , (3) , (3) , (4) , (5) , (1) , (2) , (1) , (3)
1
2
3
4
5

Abstract

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. In our recent prospective monocentric study of 117 hematopoietic stem cell adult recipients, we found that 54% and 83 % achieved a humoral response after a first and a second vaccine dose of BNT162b2 anti-SARS-CoV-2 messenger RNA respectively. In this study, we evaluated the T-cell response against the SARS-CoV-2 spike protein after two doses of vaccine in a cohort of patients allografted (N=46) for acute myeloblastic leukemia (AML, N=27) or myelodysplastic syndrome (MDS, N=19) (Table 1) and 16 healthy controls. For the 18 patients for whom we detected the highest frequencies of anti-spike CD3+ T cells, we evaluated the anti-spike responses of CD4+ and CD8+ T-cell populations as well as their functionality by testing the production of IFN-γ and TNF-α by flow cytometry.
Fichier principal
Vignette du fichier
Poster ASH 2021 Clemenceau.pdf (410.14 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03885524 , version 1 (05-12-2022)

Identifiers

  • HAL Id : inserm-03885524 , version 1

Cite

Béatrice Clémenceau, Thierry Guillaume, Marianne Coste-Burel, Pierre Peterlin, Alice Garnier, et al.. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 vaccine.. The 63rd American Society of Hematology Annual Meeting and Exposition ASH 2021, Dec 2021, Atlanta, United States. ⟨inserm-03885524⟩
0 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More